Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.50 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.50 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25284328 | 0.96 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL15488528 | 0.96 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL30485856 | 0.96 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| Silver SCHEMBL38661815 | 0.96 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| Potassium Ion SCHEMBL7881660 | 0.96 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL5969791 | 0.84 | CTSK (0.45) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL10192146 | 0.81 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL12730505 | 0.81 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL8747766 | 0.81 | CA1 (0.49) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL59323 | 0.81 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-03-24 | — | — | US | disclosed |
| EP-0424899-B1 | Novel anthracycline glycoside derivatives and preparing method thereof | DONG A PHARM CO LTD (KR) | 1997-01-22 | — | — | EP | disclosed |
| US-5220001-A | Antitumor agents | ZAIDAN HOJIM BISEIBUTSU DONG-A PHARM CO. (KR) | 1993-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | OGFR, OPRM1, CYP4F3 | CA2 2431/4885CA1 408/4885CA4 1902/4885 |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | SLC16A3, SLC16A8, SLC16A1 | CA2 321/4885CA1 379/4885CA4 80/4885 |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OGFR | CA2 2996/4885CA1 826/4885CA4 2286/4885 |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OGFR, OPRM1, CYP4F3 | CA2 2431/4885CA1 408/4885CA4 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.